Last reviewed · How we verify

Mepivacaine with Fentanyl

University Health Network, Toronto · Phase 1 active Small molecule Quality 5/100

Mepivacaine with Fentanyl is a Small molecule drug developed by University Health Network, Toronto. It is currently in Phase 1 development.

At a glance

Generic nameMepivacaine with Fentanyl
SponsorUniversity Health Network, Toronto
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mepivacaine with Fentanyl

What is Mepivacaine with Fentanyl?

Mepivacaine with Fentanyl is a Small molecule drug developed by University Health Network, Toronto.

Who makes Mepivacaine with Fentanyl?

Mepivacaine with Fentanyl is developed by University Health Network, Toronto (see full University Health Network, Toronto pipeline at /company/university-health-network-toronto).

What development phase is Mepivacaine with Fentanyl in?

Mepivacaine with Fentanyl is in Phase 1.

What are the side effects of Mepivacaine with Fentanyl?

Common side effects of Mepivacaine with Fentanyl include Leaking from insertion site, Dizziness, Knee effusion, Inflamed esophagus, Heartburn, Nausea.

Related